TickerFacts.

A business in context

WHWK research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4/A · Ownership change

    Report date 2026-09-15 · 0001995275-26-000018

  2. 4/A · Ownership change

    Report date 2026-09-15 · 0001909734-26-000011

  3. 4/A · Ownership change

    Report date 2026-09-15 · 0001821353-26-000007

  4. 4/A · Ownership change

    Report date 2026-09-15 · 0001766522-26-000017

  5. 4/A · Ownership change

    Report date 2026-09-15 · 0001754154-26-000016

  6. 4 · Ownership change

    Report date 2026-09-15 · 0001995275-26-000016

  7. 4 · Ownership change

    Report date 2026-09-15 · 0001909734-26-000009

  8. 4 · Ownership change

    Report date 2026-09-15 · 0001821353-26-000005

  9. 8-K · Current report

    Report date 2026-09-09 · 0001193125-26-388010 · Items 5.02,9.01

  10. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-337933

  11. 8-K · Current report

    Report date 2026-08-06 · 0001193125-26-337069 · Items 2.02,9.01

  12. 8-K · Current report

    Report date 2026-06-11 · 0001193125-26-269493 · Items 5.07

  13. 8-K · Current report

    Report date 2026-05-21 · 0001193125-26-234890 · Items 8.01,9.01

  14. 8-K · Current report

    Report date 2026-05-12 · 0001193125-26-220656 · Items 1.01,3.02,7.01,9.01

  15. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-212075

  16. 8-K · Current report

    Report date 2026-05-07 · 0001193125-26-210615 · Items 2.02,9.01

  17. DEF 14A · Proxy statement

    Report date 2026-04-28 · 0001193125-26-187149

  18. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-104158

  19. 8-K · Current report

    Report date 2026-03-12 · 0001193125-26-103117 · Items 2.02,9.01

  20. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-268895

  21. 8-K · Current report

    Report date 2025-11-06 · 0001193125-25-268134 · Items 2.02,9.01

  22. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-105081

  23. 8-K · Current report

    Report date 2025-08-07 · 0000950170-25-104592 · Items 2.02,9.01

  24. 8-K · Current report

    Report date 2025-06-11 · 0001193125-25-140810 · Items 5.07

  25. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001628280-25-023932

  26. 8-K · Current report

    Report date 2025-05-08 · 0001628280-25-023788 · Items 2.02,9.01

  27. DEF 14A · Proxy statement

    Report date 2025-06-11 · 0001628280-25-020311

  28. 8-K/A · Current report

    Report date 2025-03-25 · 0001193125-25-068845 · Items 9.01

  29. 10-K · Annual report

    Report date 2024-12-31 · 0001628280-25-015269

  30. 8-K · Current report

    Report date 2025-03-25 · 0001193125-25-063253 · Items 2.01,9.01

  31. 8-K · Current report

    Report date 2025-03-18 · 0001193125-25-056708 · Items 2.02,5.03,9.01

  32. 8-K · Current report

    Report date 2025-02-28 · 0001193125-25-045605 · Items 1.01,5.07,7.01,9.01

  33. 8-K · Current report

    Report date 2024-12-19 · 0001193125-24-282407 · Items 1.01,3.02,5.02,7.01,9.01

  34. 10-Q · Quarterly report

    Report date 2024-09-30 · 0001628280-24-045698

  35. 8-K · Current report

    Report date 2024-11-06 · 0001628280-24-045465 · Items 2.02,9.01

  36. SC 13D/A · Ownership disclosure

    0001193125-24-230376

  37. 8-K · Current report

    Report date 2024-09-26 · 0001193125-24-228322 · Items 8.01

  38. 8-K · Current report

    Report date 2024-09-15 · 0001193125-24-222116 · Items 5.02,9.01

  39. SC 13G · Ownership disclosure

    0000935836-24-000579

  40. SC 13G · Ownership disclosure

    0001373604-24-000079

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 23 transaction rows23AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

23 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-15
2026-09-18 · Amendment
Lennon David JamesA · Grant / award
Acquired
Stock option (right to buy)
Derivative security
193957.00.0
2026-09-15
2026-09-18 · Amendment
Lennon David JamesA · Grant / award
Acquired
Restricted Stock Units
Derivative security
193957.00.0
2026-09-15
2026-09-15
Lennon David JamesA · Grant / award
Acquired
Restricted Stock Units
Derivative security
193957.00.0
2026-09-15
2026-09-15
Lennon David JamesA · Grant / award
Acquired
Stock option (right to buy)
Derivative security
193957.00.0
2026-09-15
2026-09-18 · Amendment
Dugan MargaretA · Grant / award
Acquired
Restricted Stock Units
Derivative security
81250.00.0
2026-09-15
2026-09-18 · Amendment
Dugan MargaretA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
81250.00.0
2026-09-15
2026-09-15
Dugan MargaretA · Grant / award
Acquired
Restricted Stock Units
Derivative security
81250.00.0
2026-09-15
2026-09-15
Dugan MargaretA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
81250.00.0
2026-09-15
2026-09-18 · Amendment
Dornan DavidA · Grant / award
Acquired
Restricted Stock Units
Derivative security
85887.00.0
2026-09-15
2026-09-18 · Amendment
Dornan DavidA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
85887.00.0
2026-09-15
2026-09-15
Dornan DavidA · Grant / award
Acquired
Restricted Stock Units
Derivative security
85887.00.0
2026-09-15
2026-09-15
Dornan DavidA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
85887.00.0
2026-09-15
2026-09-18 · Amendment
BALL BRYANA · Grant / award
Acquired
Restricted Stock Units
Derivative security
91633.00.0
2026-09-15
2026-09-18 · Amendment
BALL BRYANA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
91633.00.0
2026-09-15
2026-09-15
BALL BRYANA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
91633.00.0
2026-09-15
2026-09-15
BALL BRYANA · Grant / award
Acquired
Restricted Stock Units
Derivative security
91633.00.0
2026-09-15
2026-09-18 · Amendment
Giacobello Scott M.A · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
118476.00.0
2026-09-15
2026-09-18 · Amendment
Giacobello Scott M.A · Grant / award
Acquired
Restricted Stock Units
Derivative security
118476.00.0
2026-09-15
2026-09-15
Giacobello Scott M.A · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
118476.00.0
2026-09-15
2026-09-15
Giacobello Scott M.A · Grant / award
Acquired
Restricted Stock Units
Derivative security
118476.00.0
2026-09-09
2026-09-11
Iyengar Vijay KA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
76080.00.0
2026-06-12
2026-07-30
Dalal AnupamA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
38040.00.0
2026-05-14
2026-07-30
Dalal AnupamA · Grant / award
Acquired
Common Stock1275510.03.92

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001422142Whitehawk Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names
  • Aadi Bioscience, Inc. · former SEC name · 2021-08-27 to 2025-03-18
  • Aerpio Pharmaceuticals, Inc. · former SEC name · 2017-03-17 to 2021-08-23
  • ZETA ACQUISITION CORP II · former SEC name · 2008-02-01 to 2017-03-13

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$25.98M$27.91M
2023-12-31$24.35M$26.93M
2022-12-31$15.22M$17.52M
2021-12-31$14.00M$17.41M
2020-12-31$14.00M$18.23M
2019-12-31$0$0
2018-12-31$20.16M$27.05M

Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

Explore the CPI history ↗